Turning recruitment potential into enrolment reality

Clinical trial recruitment challenges rarely stem from a lack of strategy. Today’s sponsors are investing more heavily in data, feasibility, and patient intelligence to identify the right sites and patient populations. But, as many studies have found, just because an opportunity looks promising on paper doesn’t mean it will translate into enrolment once recruitment begins.

This disconnect is often driven by practical complications: patients don’t always present as expected, referral pathways may be inconsistent, and the realities of local healthcare systems can create barriers that are difficult to identify through data alone.

In this episode of our patient- and site-centric solutions (PSCS) interview series, sponsored by IQVIA, pharmaphorum Deep Dive editor, Eloise McLennan, sits down with Karen Townsend, senior director of medical affairs at IQVIA, to discuss the growing importance of site enrolment & engagement leads.

These specialised professionals work alongside sites to uncover recruitment challenges early, using clinical expertise and localised relationships to help trial sponsors understand how patients move through care, where opportunities are missed, and, critically, what sites need to do to maintain enrolment momentum throughout study delivery.

Watch the full conversation below to learn more about site enrolment & engagement leads, and why field-based site intelligence is becoming an important differentiator between recruitment plans that look good on paper and recruitment strategies that deliver in practice.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialisation of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analysing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviours and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.